Anil K. Singhal - Jun 11, 2025 Form 4 Insider Report for Werewolf Therapeutics, Inc. (HOWL)

Role
Director
Signature
/s/ Jonathan Owen, Attorney-in-fact
Stock symbol
HOWL
Transactions as of
Jun 11, 2025
Transactions value $
$0
Form type
4
Date filed
6/13/2025, 04:10 PM
Previous filing
Feb 21, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Singhal Anil K. Director C/O WEREWOLF THERAPEUTICS, INC., 200 TALCOTT AVENUE, 2ND FLOOR, WATERTOWN /s/ Jonathan Owen, Attorney-in-fact 2025-06-13 0001982984

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HOWL Stock Option (right to buy) Award $0 +9K $0.00 9K Jun 11, 2025 Common Stock 9K $1.23 Direct F1, F2
transaction HOWL Stock Option (right to buy) Award $0 +8.36K $0.00 8.36K Jun 12, 2025 Common Stock 8.36K $1.29 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents stock options that the Reporting Person was entitled to receive pursuant to the non-employee director compensation policy of Werewolf Therapeutics, Inc. (the "Company") in effect at the time of the Reporting Person's appointment to the board of directors of the Company, which were not previously granted due to a clerical error.
F2 The option was granted on June 11, 2025. One-third of the total number of shares underlying the option vest on February 19, 2026, and the remaining shares vest thereafter in equal monthly installments until February 19, 2028, subject to continued service by the Reporting Person as a director to the Company through each applicable vesting date.
F3 The option was granted on June 12, 2025. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director.